Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2000 | Hydroxychloroquine/Azithromycine Wiki | 0.41 |
| drug149 | AT-001 Wiki | 0.41 |
| drug3516 | Quinquina-Stevia/Azythromycin Wiki | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug5084 | no intervention-mechanistic study Wiki | 0.41 |
| drug4097 | Standard diagnosis test Wiki | 0.41 |
| drug3845 | Saline Control Wiki | 0.41 |
| drug2480 | MSC Treatment Wiki | 0.41 |
| drug4683 | Viruxal Oral and Nasal Spray Wiki | 0.41 |
| drug2472 | MR-Pro-ADM Wiki | 0.41 |
| drug3300 | Plasma exchange and convalescent plasma Wiki | 0.41 |
| drug69 | 4Plants/Azythromycin Wiki | 0.41 |
| drug4692 | Vitamin D Wiki | 0.12 |
| drug3195 | Placebo Wiki | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D018746 | Systemic Inflammatory Response Syndrome NIH | 0.20 |
| D058186 | Acute Kidney Injury NIH | 0.15 |
| D016638 | Critical Illness NIH | 0.05 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.04 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.03 |
| D055371 | Acute Lung Injury NIH | 0.03 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.03 |
| D011014 | Pneumonia NIH | 0.02 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| D018352 | Coronavirus Infections NIH | 0.01 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001919 | Acute kidney injury HPO | 0.15 |
| HP:0002090 | Pneumonia HPO | 0.02 |
Navigate: Correlations HPO
There are 6 clinical trials
The study aims to investigate organ dysfunction and biomarkers in patients with suspected or verified COVID-19 during intensive care at Uppsala University Hospital.
Description: KDIGO AKI score
Measure: Acute Kidney Injury Time: During Intensive Care, an estimated average of 10 days.Description: Acute Respiratory Distress Syndrome yes/no
Measure: ARDS Time: During intensive care, an estimated average of 10 days.Description: Death within 30 days of ICU admission
Measure: 30 day mortality Time: 30 daysDescription: Death within 1 year of ICU admission
Measure: 1 year mortality Time: 1 yearDescription: Development of Chronic Kidney Disease
Measure: Chronic Kidney Disease Time: 60 days and 1 year after ICU admissionDescription: Sequential Organ Failure Score as a continuous variable
Measure: SOFA-score Time: During Intensive Care, an estimated average of 10 days.This study aims to use the regenerative and repair abilities of stem cells to fight against the harmful effects of the novel coronavirus Covid-19 and therefore develop a treatment strategy. It is known that fatalities from this virus is largely caused by its damage to lungs and other organs. As the disease progresses, these organs fail and lead to mortality. Our hope is that the stem cell transplantation from healthy donors will repair the damage caused by the virus and result in a healthy recovery.
Description: Improvement of clinical symptoms related to Covid-19 infection (fever, pneumonia, shortness of breath)
Measure: Clinical improvement Time: 3 monthsDescription: Improvement of lungs assessed by CT Scan
Measure: Lung damage improvement Time: 3 monthsDescription: Negative, measured by RT-PCR laboratory tests for the virus
Measure: Sars-Cov-2 viral infection laboratory test Time: 3 monthsDescription: Cell types and numbers
Measure: Blood test Time: 3 monthsIn the United Kingdom, there are currently 138,000 confirmed patients with coronavirus, causing 18,738 deaths. Whilst the disease may be mild in the majority of patients, a significant proportion of patients require intensive care therapy and a ventilator due to lung injury. In addition to lung injury/failure (acute respiratory distress syndrome (ARDS)), around 50% of patients admitted to intensive care develop acute kidney injury (AKI) (requiring advanced support via haemofiltration) and multi-organ failure. It is unclear why patients suffering from COVID-19 develop such severe lung injury (requiring life support or ventilation) or indeed why patients develop other organ dysfunction such as kidney injury. The investigators hypothesis that this may due to an over-reaction of the immune system particularly in the lungs. This then results in the release of various mediators and biological messengers which can be pushed into the blood bloodstream (exacerbated by positive pressure generated by the ventilator). These mediators then travel, via the blood, to other organs such as the kidney where they cause inflammation and injury of cells, resulting in organ failure. At the Imperial College London (specifically at the Hammersmith Hospital campus) the investigators are in the unique position to investigate the pathophysiology of multi-organ failure as we are a referral centre for patients with COVID-19 who have developed renal and multi-organ failure (the hospital has accepted a number of these patients from various hospitals across the region). The Division of Anaesthetics, Pain Medicine and Intensive Care at Imperial College London, headed by Professor Masao Takata, has an international reputation, investigating the mechanisms of organ injury and failure (particularly lung injury) in critical care patients (non-viral causes). The investigators would like to apply well-established methods to try and further the scientific community's knowledge of this severe and deadly viral condition. The investigators hope that this would lead to the development of medication that would treat this deadly virus.
Description: This will involve measurement of microvesicles in blood
Measure: Variation in inflammatory mediators in patients with multi-organ failure suffering from COVID-19 Time: 18 monthsDescription: This will involve measurement of microvesicles in bronchoalveolar lavage fluid
Measure: Variation in inflammatory mediators in patients with multi-organ failure suffering from COVID-19 Time: 18 monthsDescription: This will involve measurement of microvesicles in urine
Measure: Variation in inflammatory mediators in patients with multi-organ failure suffering from COVID-19 Time: 18 monthsDescription: The aforementioned inflammatory markers will be correlated with level fo lung injury which will be based upon the level of oxygen required by patients.
Measure: Correlation of inflammatory mediators in the bronchoalveolar lavage fluid with extent of lung injury (e.g. based upon oxygen requirement) Time: 18 monthsDescription: The aforementioned inflammatory markers will be measured in renal outcomes (creatinine and urine output) and cardiovascular markers (e.g. natriuretic peptides (BNP and NT pro-BNP) and Troponin).
Measure: Correlation of circulating inflammatory mediators with renal and cardiovascular markers Time: 18 monthsRationale: There is large heterogeneity in disease states of critically ill patients at ICU admittance and there is also large heterogeneity in their disease severity during ICU stay. Still, some patients may show remarkable similarities in disease patterns. There is a lack of understanding of causal mechanisms that lead to divergent outcomes in critically ill patients, and at the same time different diseases may share common underlying, yet unidentified, causal pathways that could explain similarities between different diseases. Objective: To explore the association between patient characteristics and the severity of organ failure in critically ill patients admitted to the ICU Study design: Prospective cohort study Study population: Adult critically ill patients in the ICU Intervention (if applicable): not applicable Main study parameters/endpoints: Maximum severity of organ failure observed during ICU stay measured by the maximum SOFA score and quality of life at one year follow-up
Description: The primary prognostic outcome will be the maximum SOFA score during ICU stay. The daily maximum SOFA score will be considered up to a maximum of 90 days.
Measure: Severity of organ failure observed during ICU stay Time: During ICU admission with a maximum of 90 daysDescription: Patients will be evaluated by questionnaires at 6 and 12 months follow-up.Follow-up data will include survival status and data on quality of life. Patients psychological functioning will be evaluated using the Short Form 20 and the Hospital Anxiety and Depression Scale (HADS). Patients physical functioning data will be measured by the KATZ ADL index and the Clinical Frailty Score. In addition, the Euro-Qol (EQ-5d) will be used. Social functioning data will be collected using the General Functioning 6 scale (GF6) which is a subscale of the GF12 and is a quick and effective tool to assess the overall functioning of families. Data will be collected from both patients and family members. Return to work will only be evaluated at 12 months follow-up by 4 extra questions concerning the patients return to work. In addition we will explore and validate extended modifications on the total and domain level of the organ failure assessment score (SOFA+).
Measure: Follow-up Quality of life data Time: 6 and 12 months after ICU dischargeCOVID-19 is a worldwide pandemic. Around 5% of infected patients are admitted in ICU, mainly for respiratory failure. Outcome of these patients is linked to other organ failures. Optimal therapies are not defined so far. The sponsor want to assess the role of MR-ProADM as prognostic biomarker, and the impact of treatments (including supportive treatments) on MOF occurrence and outcome.
Description: Association or correlation between MR-ProADM at day 1 and day 3 and the onset of visceral failures extra respiratory in reanimation.
Measure: Association or correlation between MR-ProADM at day 1 and day 3 and the onset of visceral failures extra respiratory in reanimation. Time: comparison to day 1 and day 3Description: mortality at day 28 and day 90.
Measure: mortality at day 28 and day 90. Time: admission until day 90Description: Association between MR-ProADM and mortality at day 28.
Measure: Association between MR-ProADM and mortality at day 28. Time: admission until day 28Description: Association or correlation between patient factor or treatment, and the onset or aggravation of visceral failures (day 3 and day 10), evolution until day 28.
Measure: Association or correlation between patient factor or treatment, and the onset or aggravation of visceral failures (day 3 and day 10), evolution until day 28. Time: admission until day 28This Randomized Control Trial (RCT) proposes combination of extracorporeal cytokine removal by plasma exchange (PLEX) and additional infusion of convalescent plasma (CCP) collected from COVID-19 recovered individuals at the end of the PLEX procedure. The combination of cytokine removal by PLEX and CCP infusion is in onvestigators opinion more rational compared to CCP infusion alone and as such probably more effective in reducing the duration of mechanical ventilation, length of stay in the intensive care unit, and potentially also mortality.
Description: The primary outcome is days alive and out of hospital from randomisation to day 90.
Measure: Alive at Day 90th Time: 90 daysDescription: Serious adverse events - new episode of septic shock, anaphylactic reaction to CCP, invasive fungal infection, TACO, TRALI.
Measure: Day 8 serious adverse events Time: 8 daysDescription: All-cause mortality at day 28
Measure: Day 28 all cause mortality Time: 28 daysDescription: Days alive without life support at day 90
Measure: Days alive without life support at day 90 Time: 90 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports